Synthesis and in vitro evaluation of α-synuclein ligands.

Synthesis and in vitro evaluation of α-synuclein ligands.
复制标题

DOI:
10.1016/j.bmc.2012.06.023
复制
发表时间:
2012-08-01
影响因子:
3.5
通讯作者:
Tu Z
Tu Z
中科院分区:
医学3区
文献类型:
--
作者:
Yu L;Cui J;Padakanti PK;Engel L;Bagchi DP;Kotzbauer PT;Tu Z

文献摘要

参考文献

被引文献

相似文献

α-突触核蛋白在Lewy小体和Lewy神经突中的聚集是帕金森病(PD)的病理标志。为了鉴定对聚集的α-突触核蛋白具有高结合效力的配体,我们合成了一系列吩噻嗪衍生物,并使用荧光硫磺素T竞争测定来评估它们与重组α-突触核蛋白原纤维的结合亲和力。在16个新的类似物中,体外数据表明化合物11 b对α-突触核蛋白纤维具有高亲和力(Ki = 32.10 ± 1.25 nM),化合物11 d、16 a和16 b对α-突触核蛋白纤维具有中等亲和力(Ki = 50至100 nM)。进一步优化这些类似物的结构可能会产生对聚集的α-突触核蛋白具有高亲和力和选择性的化合物。
Accumulation of misfolded α-synuclein in Lewy bodies and Lewy neurites is the pathological hallmark of Parkinson’s Disease (PD). To identify ligands having high binding potency toward aggregated α-synuclein, we synthesized a series of phenothiazine derivatives and assessed their binding affinity to recombinant α-synuclein fibrils using a fluorescent thioflavin T competition assay. Among 16 new analogues, the in vitro data suggest that compound 11b has high affinity to α-synuclein fibrils (Ki = 32.10 ± 1.25 nM) and compounds 11d, 16a and 16b have moderate affinity to α-synuclein fibrils (Ki ≈ 50 to 100 nM). Further optimization of the structure of these analogues may yield compounds with high affinity and selectivity for aggregated α-synuclein.
DOI: 10.1007/s00401-008-0344-8
发表时间: 2008-04-01
影响因子: 12.7
作者:
Halliday, Glenda;Hely, Mariese;Morris, John
通讯作者: Morris, John
DOI: 10.1016/j.ejmech.2011.03.003
发表时间: 2011-06-01
影响因子: 6.7
作者:
Gonzalez-Munoz, Gema C.;Arce, Mariana R.;Isabel Rodriguez-Franco, Maria
通讯作者: Isabel Rodriguez-Franco, Maria
DOI: 10.1001/archneur.65.12.1577
发表时间: 2008-12-01
影响因子: --
作者:
Kazantsev, Aleksey G.;Kolchinsky, Alexander M.
通讯作者: Kolchinsky, Alexander M.
DOI: 10.1186/1750-1326-5-55
发表时间: 2010-12-07
影响因子: 15.1
作者:
Bate C;Gentleman S;Williams A
通讯作者: Williams A
DOI: 10.1002/ana.20009
发表时间: 2004-03-01
影响因子: 11.2
作者:
Klunk, WE;Engler, H;Långström, B
通讯作者: Långström, B